Holen Sie sich die Stockscreener-App
13.94
4.26%
-0.62
Handel nachbörslich:
13.98
0.04
+0.29%
Schlusskurs vom Vortag:
$14.56
Offen:
$14.15
24-Stunden-Volumen:
1.21M
Relative Volume:
2.26
Marktkapitalisierung:
$835.48M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-11.32%
1M Leistung:
-19.14%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$13.27
$14.46
1-Wochen-Bereich:
$13.27
$15.79
52-Wochen-Spanne:
$8.89
$24.36
Beta Bionics Inc Stock (BBNX) Company Profile
Firmenname
Beta Bionics Inc
Sektor
Branche
Telefon
949-427-7785
Adresse
11 HUGHES, IRVINE
Vergleichen Sie BBNX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BBNX
Beta Bionics Inc
|
13.94 | 835.48M | 0 | 0 | 0 | 0.00 |
|
ABT
Abbott Laboratories
|
136.26 | 233.36B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
104.78 | 147.06B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
396.74 | 145.64B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
88.75 | 112.76B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.18 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
Beta Bionics Inc Stock (BBNX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-16 | Eingeleitet | Truist | Buy |
| 2025-06-12 | Eingeleitet | Lake Street | Buy |
| 2025-05-30 | Eingeleitet | Goldman | Neutral |
| 2025-05-30 | Eingeleitet | Wolfe Research | Outperform |
| 2025-02-24 | Eingeleitet | BofA Securities | Buy |
| 2025-02-24 | Eingeleitet | Lake Street | Buy |
| 2025-02-24 | Eingeleitet | Leerink Partners | Outperform |
| 2025-02-24 | Eingeleitet | Piper Sandler | Overweight |
| 2025-02-24 | Eingeleitet | Stifel | Buy |
| 2025-02-20 | Eingeleitet | Ladenburg Thalmann | Neutral |
| 2025-02-20 | Eingeleitet | Robert W. Baird | Neutral |
Alle ansehen
Beta Bionics Inc Aktie (BBNX) Neueste Nachrichten
Global Artificial Pancreas Devices Market is Gearing Up for Outstanding Expansion at a CAGR of ~16% by 2032 | DelveInsight - GlobeNewswire Inc.
Beta Bionics (NASDAQ:BBNX) Now Covered by Truist Financial - Defense World
Beta Bionics initiated with a Buy at Truist - TipRanks
Beta Bionics, Inc.: Strategic Growth and Market Penetration with iLet Infusion Pump - TipRanks
Beta Bionics stock initiated with Buy rating at Truist Securities By Investing.com - Investing.com South Africa
Beta Bionics stock initiated with Buy rating at Truist Securities - Investing.com
Lake Street Capital Initiates Coverage on Beta Bionics (NASDAQ:BBNX) - Defense World
Beta Bionics, Inc. (NASDAQ:BBNX) Receives $23.13 Average Price Target from Brokerages - Defense World
Beta Bionics Executives Unload Shares in Major Stock Sell-Off! - TipRanks
Beta Bionics CEO, CFO on how to take a company public - MedTech Dive
Goldman Sachs Bullish On Dexcom And Insulet As Diabetes Tech Surges - Benzinga
Wolfe Research Initiates Coverage of Beta Bionics (BBNX) Stock with Outperform Rating - Insider Monkey
Beta Bionics (NASDAQ:BBNX) Now Covered by The Goldman Sachs Group - Defense World
Beta Bionics (NASDAQ:BBNX) Coverage Initiated by Analysts at Wolfe Research - Defense World
Goldman Sachs Initiates Coverage of Beta Bionics (BBNX) with Neutral Recommendation - Nasdaq
Goldman Sachs sets Beta Bionics stock at Neutral with $16 target - Investing.com Australia
Beta Bionics initiated with an Outperform at Wolfe Research - TipRanks
Beta Bionics Stock Gains After Mixed Analyst Coverage; Wolfe Bullish, Goldman Neutral - Asianet Newsable
Beta Bionics initiated with a Neutral at Goldman Sachs - TipRanks
The medtech IPO window is finally open. Or is it? - MedTech Dive
Diabetes Dialogue: Real-World Impact of iLet Bionic Pancreas, With Steven Russell, MD, PhD - HCPLive
Midday Stock Roundup: RxSight Up 13% on Wells Fargo Upgrade - Orange County Business Journal
Positive Developments and Strategic Advancements Drive Buy Rating for Beta Bionics, Inc. - TipRanks
Transcript : Beta Bionics, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 09 - marketscreener.com
Brokerages Set Beta Bionics, Inc. (NASDAQ:BBNX) Price Target at $24.83 - Defense World
Beta Bionics Q1 2025 Earnings: Strong Growth and Optimism - TipRanks
Strong Performance and Growth Potential: Buy Rating for Beta Bionics, Inc. - TipRanks
Earnings call transcript: Beta Bionics Q1 2025 earnings miss estimates - Investing.com Australia
Earnings call transcript: Beta Bionics Q1 2025 earnings miss estimates By Investing.com - Investing.com UK
Positive Developments and Strong Financial Performance Drive Buy Rating for Beta Bionics, Inc. - TipRanks
Beta Bionics Reports First Quarter 2025 Financial Results and Raises Annual Guidance for Full Year 2025 - GlobeNewswire
Beta Bionics Inc (BBNX) Q1 2025 Earnings Call Highlights: Strong Sales Growth and Strategic ... By GuruFocus - Investing.com Canada
Beta Bionics Reports Strong Q1 2025 Results and Raises Guidance - TipRanks
Beta Bionics Q1 2025 slides: raised guidance despite earnings miss - Investing.com
Beta Bionics Q1 2025 slides: raised guidance despite earnings miss By Investing.com - Investing.com South Africa
Beta Bionics Q1 2025 Earnings Call Transcript - MarketBeat
Critical Review: Beta Bionics (NASDAQ:BBNX) and INVO Bioscience (NASDAQ:INVO) - Defense World
Beta Bionics Inc expected to post a loss of 48 cents a shareEarnings Preview - TradingView
Highest quarter in years as med-tech raises $8B in Q1 financings - BioWorld MedTech
Beta Bionics to Present at the Bank of America Securities Health Care Conference - The Manila Times
Beta Bionics: Slowing Down Or Being Conservative? (NASDAQ:BBNX) - Seeking Alpha
Beta Bionics, Inc. (NASDAQ:BBNX) Receives $24.83 Average Target Price from Analysts - Defense World
beta bionics, inc., Earnings dates - RTTNews
Beta Bionics to Announce First Quarter 2025 Financial Results on May 6, 2025 - The Manila Times
Beta Bionics, Inc. to Release First Quarter 2025 Financial Results on May 6, 2025 - Nasdaq
Finanzdaten der Beta Bionics Inc-Aktie (BBNX)
Es liegen keine Finanzdaten für Beta Bionics Inc (BBNX) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Beta Bionics Inc-Aktie (BBNX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Hopman Mark | Chief Commercial Officer |
Jun 02 '25 |
Sale |
17.89 |
868 |
15,529 |
34,132 |
| Russell Steven Jon | Chief Medical Officer |
Jun 02 '25 |
Sale |
17.89 |
1,039 |
18,588 |
72,032 |
| Mensinger Mike | Chief Product Officer |
Jun 02 '25 |
Sale |
17.89 |
1,115 |
19,948 |
92,904 |
| Feider Stephen | Chief Financial Officer |
Jun 02 '25 |
Sale |
17.89 |
1,497 |
26,783 |
45,503 |
| Saint Sean | President & CEO |
Jun 02 '25 |
Sale |
17.89 |
3,439 |
61,526 |
104,561 |
| Mensinger Mike | Chief Product Officer |
Jan 31 '25 |
Buy |
17.00 |
33,350 |
566,950 |
59,019 |
| Mensinger Mike | Chief Product Officer |
Jan 31 '25 |
Sale |
17.00 |
13 |
221 |
25,669 |
| Wellington Hadley Harbor Aggre | 10% Owner |
Jan 31 '25 |
Buy |
17.00 |
1,000,000 |
17,000,000 |
3,901,599 |
4.52%
0.92%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):